Establishment of Hong Kong Diabesity Register

All participants of the Diabesity Register will receive structured assessment by nurses guided by the JADE portal at baseline including eye, feet, blood and urine examination with evaluation of BMI, blood pressure, HbA1c, lipid profile, renal and liver function tests, urine for albumin-creatinine ratio. All patients will return at 3-year for a repeat assessment of physical and psychological health, as well as changes over time.

Study Overview

• Status: Recruiting
• Conditions: Diabesity
• Intervention / Treatment: Other: No Intervention: Observational Cohort

• Study Type: Observational
• Enrollment (Estimated): 800

Contacts and Locations

• Study Contact: Name: Alice Pik Shan Kong, MD; Phone Number: +852 3505 2648; Email: alicekong@cuhk.edu.hk

Study Locations

• Hong Kong
  • Hong Kong, Hong Kong
    • Recruiting
    • Department of Medicine and Therapeutics, The Chinese University of Hong Kong (CUHK), Ward 3M, Diabetes and Endocrine Research Centre, 3/F Day Treatment Block and Children Wards (Old Block), Prince of Wales Hospital
    • Contact: Alice Pik Shan Kong, MD; Phone Number: +852 3505 2648; Email: alicekong@cuhk.edu.hk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

All study subjects will be recruited from the Diabetes Mellitus and Endocrine Centre (DMEC) at PWH. Since 1995, the PWH runs a comprehensive complication screening program as part of a quality improvement program in the DMEC. On a weekly basis, patients with diabetes mellitus undergo comprehensive assessments for risk factors and complications by nurses and health care assistants using standard protocols.

Description

Inclusion Criteria:

1. Type 2 diabetes;
2. Obesity reaching action level as defined as body mass index (BMI) 27.5 kg/m2 and/or waist circumference (WC) 80cm in women and 90cm in men;
3. Age between 18 and 50 years;
4. Able to conversate with smartphone technology and web-based program.
5. Able to read Chinese and communicate using Chinese.

Exclusion Criteria:

1. Type 1 diabetes;
2. Active malignant disease including those with history of malignant disease less than 5 years of disease-free duration;
3. Life expectancy less than 12 months;
4. Any medical illness or condition as judged by the investigators as ineligible to participate the study.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Diabesity; People with diabetes and obesity	Other: No Intervention: Observational Cohort; It is an registry so no intervention will be used.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
A composite of incidence	Incidence of diabetes-related complications	3 years

Secondary Outcome Measures

Outcome Measure	Time Frame
Incidence of diabetic mellitus retinopathy	3 years
Incidence of diabetic mellitus nephropathy	3 years
Incidence of diabetic mellitus neuropathy	3 years
Incidence of myocardial infarction	3 years
Incidence of stroke	3 years
Incidence of peripheral artery disease	3 years

Collaborators and Investigators

• Sponsor: Chinese University of Hong Kong

Study record dates

Study Major Dates

• Study Start (Actual): October 22, 2025
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2029

Study Registration Dates

• First Submitted: November 18, 2025
• First Submitted That Met QC Criteria: November 18, 2025
• First Posted (Actual): November 25, 2025

Study Record Updates

• Last Update Posted (Actual): November 25, 2025
• Last Update Submitted That Met QC Criteria: November 18, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Body Weight; Diabetes Mellitus; Diabetes Complications; Overweight; Obesity; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Diabesity
• Other Study ID Numbers: CRE 2025.324 register

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No